INS and metabolic dysfunction-associated steatotic liver disease: Quartile-based analysis indicated that individuals in the highest insulin group (Q4) had significantly higher odds of having NAFLD compared with those in the lowest insulin group (Q1; OR = 3.61; 95% CI 1.84–7.08; P = .006).